Cargando…
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM. The primary endpoints were the maximum...
Autores principales: | DeAngelo, Daniel J., Radia, Deepti H., George, Tracy I., Robinson, William A., Quiery, Albert T., Drummond, Mark W., Bose, Prithviraj, Hexner, Elizabeth O., Winton, Elliott F., Horny, Hans-Peter, Tugnait, Meera, Schmidt-Kittler, Oleg, Evans, Erica K., Lin, Hui-Min, Mar, Brenton G., Verstovsek, Srdan, Deininger, Michael W., Gotlib, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674134/ https://www.ncbi.nlm.nih.gov/pubmed/34873347 http://dx.doi.org/10.1038/s41591-021-01538-9 |
Ejemplares similares
-
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
por: Gotlib, Jason, et al.
Publicado: (2021) -
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022) -
P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
por: Gotlib, Jason, et al.
Publicado: (2023) -
Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021) -
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)